EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Shirley Xerxes was one of the first in the UK to receive the injectable form of Keytruda on the NHS A new injectable form of a key cancer drug could see thousands of NHS patients across the UK ...

Health Minister Mike Nesbitt has confirmed that a key injectable cancer drug which can be used to treat multiple cancers is being used in three of Northern Ireland's five health trusts. Pembrolizumab ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...

I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how scarcity shapes life and death decisions.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.